|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPR22 |
Gene summary for GPR22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPR22 | Gene ID | 2845 |
| Gene name | G protein-coupled receptor 22 | |
| Gene Alias | GPR22 | |
| Cytomap | 7q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A4D0R8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2845 | GPR22 | S027 | Human | Liver | HCC | 1.62e-09 | 4.41e-01 | 0.2446 |
| 2845 | GPR22 | S028 | Human | Liver | HCC | 5.55e-24 | 6.98e-01 | 0.2503 |
| 2845 | GPR22 | S029 | Human | Liver | HCC | 3.97e-33 | 1.08e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPR22 | SNV | Missense_Mutation | rs752096556 | c.748C>A | p.Gln250Lys | p.Q250K | Q99680 | protein_coding | tolerated(0.45) | benign(0.024) | TCGA-A7-A26F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| GPR22 | SNV | Missense_Mutation | novel | c.1286N>G | p.Gln429Arg | p.Q429R | Q99680 | protein_coding | tolerated_low_confidence(0.46) | benign(0.005) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GPR22 | insertion | Frame_Shift_Ins | novel | c.496_497insT | p.Ser168PhefsTer11 | p.S168Ffs*11 | Q99680 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GPR22 | insertion | Frame_Shift_Ins | novel | c.1233_1234insA | p.Ile414AsnfsTer4 | p.I414Nfs*4 | Q99680 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GPR22 | SNV | Missense_Mutation | novel | c.1000A>G | p.Thr334Ala | p.T334A | Q99680 | protein_coding | deleterious(0.04) | benign(0.297) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GPR22 | SNV | Missense_Mutation | novel | c.177C>A | p.Asn59Lys | p.N59K | Q99680 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-HM-A3JJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| GPR22 | SNV | Missense_Mutation | c.1159N>A | p.Val387Ile | p.V387I | Q99680 | protein_coding | deleterious(0.02) | benign(0.331) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GPR22 | SNV | Missense_Mutation | novel | c.782C>A | p.Ser261Tyr | p.S261Y | Q99680 | protein_coding | deleterious(0.01) | possibly_damaging(0.892) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GPR22 | SNV | Missense_Mutation | c.801N>T | p.Glu267Asp | p.E267D | Q99680 | protein_coding | tolerated(0.31) | possibly_damaging(0.664) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GPR22 | SNV | Missense_Mutation | novel | c.782C>A | p.Ser261Tyr | p.S261Y | Q99680 | protein_coding | deleterious(0.01) | possibly_damaging(0.892) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |